Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,009 public trials 2,034 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.

NCT00532675

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • UCSF Medical Center San Francisco, California, United States
  • Emory University School of Medicine/Winship Cancer Institute Dept. of Winship Cancer Inst. Atlanta, Georgia, United States
  • St. Vincent's Comprehensive Cancer Center New York, United States
  • Novartis Investigative Site South Brisbane, Queensland, Australia
View Trial Details
Completed

Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma

NCT01854606

Conditions
CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Washington University School of Medicine Dept of Oncology. St Louis, Missouri, United States
  • Memorial Sloan Kettering Cancer Center Onc. Dept. New York, United States
  • Sarah Cannon Research Institute Dept of Onc Nashville, Tennessee, United States
  • Novartis Investigative Site Rouen, France
View all 15 locations
View Trial Details
Completed

Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation

NCT01058434

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • University of South Alabama / Mitchell Cancer Institute Dept. of Mitchell Cancer Inst. Mobile, Alabama, United States
  • Central Hematology Oncology Medical Group Alhambra, California, United States
  • Central Coast Medical Oncology Corporation Santa Maria, California, United States
  • St. Jude Heritage Medical Group Virginia Crosson Cancer Center Yorba Linda, California, United States
View all 30 locations
View Trial Details
Completed

Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma

NCT00532389

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Innovative Medical Research of South Florida Dept.ofInnovativeMedResearch Miami Shores, Florida, United States
  • Dana Farber Cancer Institute Clinical Research Coordinator Boston, Massachusetts, United States
  • Hackensack University Medical Center Multiple Myeloma Division Hackensack, New Jersey, United States
  • Swedish Medical Center Dept.ofSwedishMedicalCtr. Seattle, Washington, United States
View all 16 locations
View Trial Details
Completed

Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies

NCT00670592

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Hodgkin's Lymphoma, +9 more
Locations
  • Northwestern University Chicago, Illinois, United States
  • St. Francis Cancer Research Foundation Dept.ofSt.FrancisCancerRes.(2) Beech Grove, Indiana, United States
  • Dana Farber Cancer Institute SC-5 Boston, Massachusetts, United States
  • Wake Forest University Baptist Medical Center Dept. of Industry Research (2) Winston-Salem, North Carolina, United States
View all 28 locations
View Trial Details
Completed

Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma

NCT01302886

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +7 more
Locations
  • Highlands Oncology Group Dept of Highlands Oncology Grp Fayetteville, Arkansas, United States
  • H. Lee Moffitt Cancer Center & Research Institute SC - 3 Tampa, Florida, United States
  • Emory University School of Medicine/Winship Cancer Institute Dept. of Hematology (2) Atlanta, Georgia, United States
  • Indiana University Indiana Univ Indianapolis, Indiana, United States
View all 13 locations
View Trial Details
Completed

Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma

NCT02144038

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(SC) Houston, Texas, United States
  • Seattle Cancer Care Alliance Oncology Dept Seattle, Washington, United States
  • University of Wisconsin / Paul P. Carbone Comp Cancer Center Dept of Onc. Madison, Wisconsin, United States
  • Novartis Investigative Site Prahran, Victoria, Australia
View Trial Details

Related conditions